摘要
目的比较FOLFOX与XELOX化疗方案治疗老年晚期胃癌患者的疗效及对外周血T淋巴细胞亚群的影响。方法选取本院2016年5月至2018年4月收治的老年晚期胃癌患者72例,随机分为对照组和观察组,各36例。对照组采用FOLFOX方案治疗,观察组采用XELOX方案治疗。比较两组治疗前、治疗7 d后CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平变化,近期疗效及临床不良反应情况。结果治疗7 d后,两组CD3^+、CD4^+、CD4^+/CD8^+水平均升高,CD8+水平均降低(P<0.05);观察组治疗7 d后CD3^+、CD4^+、CD4^+/CD8^+水平均高于对照组,CD8^+水平低于对照组(P<0.05);两组临床有效治疗率、病情控制率比较差异无统计学意义,观察组呕吐、腹泻、神经毒性发生率低于对照组(P<0.05),两组肝功异常、血液毒性反应发生率比较差异无统计学意义。结论FOLFOX与XELOX化疗方案均为老年晚期胃癌患者的有效治疗手段,相较于FOLFOX方案,XELOX方案在改善患者免疫功能及临床不良反应方面更具优势。
Objective To compare the efficacy of FOLFOX and XELOX regimens in the treatment of elderly patients with advanced gastric cancer and their effects on T lymphocyte subsets in peripheral blood.Methods 72 elderly patients with advanced gastric cancer admitted to our hospital from May 2016 to April 2018 were randomly divided into control group and observation group,with 36 cases in each group.The control group was treated with FOLFOX regimen,while the observation group was treated with XELOX regimen.The levels of CD3^+,CD4^+,CD8^+,CD4^+/CD8^+,shortterm efficacy and clinical toxicity were compared between the two groups before treatment and 7 days after treatment.Results After 7 days of treatment,the levels of CD3^+,CD4^+,CD4^+/CD8^+increased and CD8+decreased in both groups(P<0.05).The levels of CD3^+,CD4^+,CD4^+/CD8^+in the observation group were higher than those in the control group,and CD8+was lower than that in the control group(P<0.05).There was no significant difference in the effective treatment rate and disease control rate between the two groups.The incidence of vomiting,diarrhea and neurotoxicity in the observation group was lower than that in the control group(P<0.05),there was no significant difference in the incidence of liver dysfunction and blood toxicity between the two groups.Conclusion Both FOLFOX and XELOX regimens are effective therapies for elderly patients with advanced gastric cancer.Compared with FOLFOX regimen,XELOX regimen has more advantages in improving immune function and clinical toxicity.
作者
王洪云
夏小龙
邹彩亮
吴燕玲
钟梅
Wang Hongyun;Xia Xiaolong;Zou Cailiang;Wu Yanling;Zhong Mei(Department of Oncology,Jiujiang Third People's Hospital,Jiangxi Province,Jiujiang,Jiangxi,332000,China)
出处
《当代医学》
2020年第6期76-78,共3页
Contemporary Medicine
